Protheragen, Inc. and Enbo Life Science (Beijing) Co., Ltd. have officially signed a strategic cooperation agreement. The two companies will engage in deep collaboration across areas such as the globalization of innovative life science projects, industrial resource synergies, and international partnership expansion, while exploring cross-industry resource collaboration opportunities. The partnership brings together Protheragen’s strengths in cross-border incubation and global BD networks with Enbo Life Science’s end-to-end capabilities in the life sciences sector, spanning from R&D to commercial launch.
Against the backdrop of accelerating global life science industry integration and cross-border collaboration, this strategic partnership creates stronger connections between international BD and cross-border collaboration capabilities with domestic industrial resources and full-lifecycle project support.
Enbo Life Science is a platform organization focused on life science industry investment and enablement. With experience in technology transfer, industrial investment, and M&A, Enbo Life Science provides comprehensive support for Chinese biopharmaceutical companies from R&D through commercialization. The company is committed to establishing a diversified collaboration network with global partners, building a multi-dimensional collaboration framework that connects Chinese innovation, advanced manufacturing, and global market expansion.
Protheragen possesses specialized expertise in cross-border biopharmaceutical investment, project incubation, and international BD collaboration. Leveraging its overseas industrial network, Protheragen supports innovative projects in identifying overseas partnership opportunities, connecting resources, and advancing cross-border collaboration. Protheragen is dedicated to facilitating the effective alignment of Chinese life science innovations with international industrial resources.
Capitalizing on the respective strengths of both parties in life science industry resources, cross-border execution, and global growth, Protheragen and Enbo Life Science will pursue in-depth collaboration around the international development of innovative life science projects.
Moving forward, through resource sharing and complementary strengths, both parties will drive more efficient connections and value realization for promising life science projects, technology platforms, and industrial resources on a global scale. Both parties will explore diverse collaboration pathways for innovative outcomes—from R&D and industrialization to international market expansion.
Leveraging Enbo Life Science's capabilities in life science resource integration, project enablement, and domestic innovation ecosystem connectivity, alongside Protheragen's experience in overseas industrial networks, international BD, and cross-border cooperation, both parties will support Chinese life science innovators in connecting with the global market while fostering deep integration between domestic innovation and international industry resources.
Enbo Life Science is a global industry enablement platform focusing on cutting-edge life sciences. Headquartered in Beijing, the company maintains offices in Shanghai, Chengdu, and Hong Kong. With the goal of investing in high-value pharmaceutical assets, Enbo Life Science connects global pharmaceutical industry resources. Its core businesses include equity investment, pharmaceutical asset investment, NewCo creation, cross-border out-licensing/BD, and product sales. Enbo Life Science focuses on globally competitive innovative therapeutics and medical devices, including but not limited to: cutting-edge drug delivery technologies, cell and gene therapies, novel antibody drugs and modalities, innovative applications of AI in life sciences, and the global adoption of digital healthcare. Enbo Life Science empowers Chinese scientists and enterprises across technology translation, patent strategy, product development, commercialization, fundraising, and M&A.
Headquartered in New York, USA, Protheragen Inc. is a company deeply rooted in the global pharmaceutical and biomedical sectors. We have long been dedicated to providing biotechnology and pharmaceutical companies with comprehensive investment, incubation, and international expansion support services. We boast a dynamic and well-structured team of professionals committed to fostering and facilitating collaborative opportunities within the global pharmaceutical industry to advance the development of innovative medicine. Core to our team are biomedical Ph.D.s from top U.S. universities who leverage strategic market advantages to navigate the complexities of the pharmaceutical landscape and build bridges for cross-border collaboration.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
